ELISA Kit for Plasminogen Activator Inhibitor 1 (PAI1) Homo sapiens (Human) Sandwich ELISA

SERPINE1; PLANH1; Serpin Peptidase Inhibitor Clade E Member 1; Nexin,Plasminogen Activator Inhibitor Type 1 Serpin E1; Endothelial plasminogen activator inhibitor

  • Product No.SEA532Hu
  • Organism SpeciesHomo sapiens (Human) Same name, Different species.
  • Sample Typeplasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
  • Test MethodDouble-antibody Sandwich
  • Assay Length3h
  • Detection Range12.5-800pg/mL
  • SensitivityThe minimum detectable dose of this kit is typically less than 5.5pg/mL.
  • Specificity This assay has high sensitivity and excellent specificity for detection of Plasminogen Activator Inhibitor 1 (PAI1).No significant cross-reactivity or interference between Plasminogen Activator Inhibitor 1 (PAI1) and analogues was observed.
  • ApplicationsEnzyme-linked immunosorbent assay for Antigen Detection.
  • DownloadInstruction Manual
  • UOM 48T96T 96T*5 96T*10 96T*100 Ensure in stock; if not, free redo!
  • FOB US$ 349.00 US$ 498.00 US$ 2,241.00 US$ 4,233.00 US$ 34,860.00
  • Quantity
  • Add to Cart Distributors
  • ELISA Kit for Plasminogen Activator Inhibitor 1 (PAI1) Packages (Simulation)
  • ELISA Kit for Plasminogen Activator Inhibitor 1 (PAI1) Packages (Simulation)
  • ELISA Kit for Plasminogen Activator Inhibitor 1 (PAI1) Results demonstration
  • SEA532Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Plasminogen Activator Inhibitor 1 (PAI1) and the recovery rates were calculated by comparing the measured value to the expected amount of Plasminogen Activator Inhibitor 1 (PAI1) in samples.

Matrix Recovery range (%) Average(%)
sodium citrate plasma(n=5) 80-101 91

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Plasminogen Activator Inhibitor 1 (PAI1) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Plasminogen Activator Inhibitor 1 (PAI1) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Plasminogen Activator Inhibitor 1 (PAI1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
sodium citrate plasma(n=5) 91-99% 79-90% 91-99% 90-99%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
TMB Substrate 1×9mL Stop Solution 1×6mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
8. Add 50µL Stop Solution. Read at 450nm immediately.

ELISA Kit for Plasminogen Activator Inhibitor 1 (PAI1)

Test principle

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Plasminogen Activator Inhibitor 1 (PAI1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Plasminogen Activator Inhibitor 1 (PAI1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Plasminogen Activator Inhibitor 1 (PAI1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Plasminogen Activator Inhibitor 1 (PAI1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Reference

  • Breast Cancer Research and TreatmentOral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c miceSpringerLink: f3w831267267p277
  • Clin Appl Thromb Hemost.Is There Any Association Between Thrombosis and Tissue Factor Pathway Inhibitor Levels in Patients With Vitamin D Deficiency?Pubmed: 24203351
  • Molecular Nutrition & Food ResearchTrans‐fatty acid promotes thrombus formation in mice by aggravating antithrombogenic endothelial functions via Toll‐like receptorsPubMed: 25546502
  • Archives of Physiology and BiochemistryActivation of cardiac renin–angiotensin system and plasminogen activator inhibitor-1 gene expressions in oral contraceptive-induced cardiometabolic disorderPubmed:26934364
  • Naunyn-Schmiedeberg's Archives of PharmacologyCombined oral contraceptive-induced hypertension is accompanied by endothelial dysfunction and upregulated intrarenal angiotensin II type 1 receptor gene expressionpubmed:27447455
  • Environmental toxicology and pharmacologyCombined oral contraceptive and nitric oxide synthesis inhibition synergistically causes cardiac hypertrophy and exacerbates insulin resistance in female rats.pubmed:28376377
  • Annals of Clinical & Laboratory ScienceAlteration of Hemostatic Parameters in Patients with Different Levels of Subclinical Hypothyroidism and the Effect of L-thyroxine Treatmentpubmed:28249913

Recommend products